Drug Research
ST Pharm and Quantoom Partner to Enhance RNA Manufacturing Flexibility
ST Pharm and Quantoom Biosciences have announced an extended collaboration to advance the development and manufacturing of RNA-based vaccines and therapeutics. This partnership integrates the complementary strengths of both companies to enhance the global supply of critical RNA manufacturing...
Drug Research
Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
Bridge Biotherapeutics, a clinical-stage biotech company, announced that it has entered into a joint research agreement with HitGen Inc., a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen’s DNA-encoded...
Drug Research
Novartis and Versant Ventures Launch Borealis Biosciences with $150M Investment
Novartis and Versant Ventures have launched Borealis Biosciences with a substantial $150 million Series A funding. The new biotech firm aims to develop next-generation xRNA-based medicines targeting kidney diseases. This venture marks a significant milestone in renal medicine and...
Drug Research
Bridge Biotherapeutics and HitGen Initiate Research Collaboration to Advance Novel Cancer Therapeutics Program
Bridge Biotherapeutics, a clinical-stage biotech company announced that it has entered into a joint research agreement with HitGen Inc., a Chinese drug discovery platform company. This collaboration builds on successful initial hit finding and identification work from HitGen's DNA-encoded...
Drug Research
FUJIFILM Diosynth Biotechnologies Celebrates Opening of Billingham, UK Microbial Manufacturing Facility
FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, vaccines, advanced therapies, and oncolytic viruses hosted a celebration for the opening of its microbial fermentation manufacturing facility in Billingham. This new facility triples existing...
Drug Research
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced that it has entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic.
HT-KIT research, which was conducted at NC State University to evaluate the efficacy of HT-KIT...
Drug Research
Tonix advances development of TNX-801 to prevent mpox infection
Tonix Pharmaceuticals Holding Corp., a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, has reiterated its commitment to advance development of its live attenuated virus vaccine, TNX-801 , for preventing mpox and other infectious diseases....
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read